Steatohepatitis/Metabolic Liver Disease News

Eli Lilly presented data from several studies of tirzepatide, an investigational dual gastric inhibitory polypeptide and glucagonlike peptide1 receptor agonist, that showed its potential to treat metabolic conditions including type 2 diabetes and nonalcoholic steatohepatitis.

Eiger Pharmaceuticals appointed Jeysen Yogaratnam, MRCSEd, PhD, to vice president of the company’s global hepatitis delta virus clinical development program, according to a press release.

Genfit initiated a phase 2 trial to evaluate the effect of elafibranor on hepatic lipid composition in patients with nonalcoholic fatty liver disease, according to a press release.

Fatty liver experts discussed the necessity of revising current common nomenclature of nonalcoholic fatty liver disease and alcoholic fatty liver disease to better reflect clinical phenotype based on growing prevalence and overlapping features of both classifications.

In the ongoing pursuit to find treatments for nonalcoholic fatty liver disease, researchers have focused on discerning which diet and exercise interventions may be the most successful, which current therapeutics such as daily use of aspirin may improve hepatic parameters, while continuing to develop prediction tools.

A combination of pioglitazone and vitamin E can lead to better liver histology in adults with type 2 diabetes, but treatment with vitamin E alone does not provide substantial benefits, suggesting that the vitamin does not play as large a role in the combination therapy, according to findings published in Diabetes Care.

Akero Therapeutics screened the first patient for a phase 2a clinical trial of AKR-001, an Fc-FGF21 fusion protein under investigation for the treatment of nonalcoholic steatohepatitis, according to a press release.

89bio announced positive top-line results from a phase 1 study of BIO89-100, a novel long-acting glycopegylated fibroblast growth factor 21 analogue under investigation for the treatment of nonalcoholic steatohepatitis, according to a press release.

The market research agency NetNoggin released its newest research known as NetNog: #genesis NASH, which includes data on nonalcoholic steatohepatitis and nonalcoholic fatty liver disease for pharmaceutical development, according to a press release.

SAN DIEGO — Patients with NASH who underwent bariatric surgery were no more likely to undergo liver transplantation surgery than those without a history of bariatric surgery, according to a study presented at Digestive Disease Week.